PARP inhibitors in the management of breast cancer: current data and future prospects

Table 4 Ongoing and recruiting phase 2/3 studies

Study name (NCT)	Ref.	Phase	Setting	Investigational arm(s)	Comparator arm(s)	Primary endpoint	Study status
Olaparib
OlympiAD	[62]	3	ADV	Olaparib monotherapy	Physician’s choice CT	PFS	R
(NCT02000622)	[62]	3	ADV	Olaparib monotherapy	Physician’s choice CT	PFS	R
OlympiA	[68]	3	ADJ	Olaparib monotherapy	Placebo	IDFS	R
(NCT02032823)	[68]	3	ADJ	Olaparib monotherapy	Placebo	IDFS	R
Veliparib
BROCADE	[96]	2	ADV	Veliparib +	Placebo +	PFS	R
(NCT01506609)				(Temozolomide) or	CBDCA + PTX
(NCT01506609)				(CBDCA + PTX)	CBDCA + PTX
(NCT02163694)	[63]	3	ADV	Veliparib +	Placebo +	PFS	R
(NCT02163694)	[63]	3	ADV	CBDCA + PTX	CBDCA + PTX	PFS	R
Brightness	[74]	3	NADJ	(Veliparib + CBDCA) or (Placebo + CBDCA) + Neoadjuvant CT	Placebo + Neoadjuvant CT	pCR rate	R
(NCT02032277)	[74]	3	NADJ	(Veliparib + CBDCA) or (Placebo + CBDCA) + Neoadjuvant CT	Placebo + Neoadjuvant CT	pCR rate	R
Talazoparib
EMBRACA	[61]	3	ADV	Talazoparib monotherapy	Physician’s choice CT	PFS	R
(NCT01945775)	[61]	3	ADV	Talazoparib monotherapy	Physician’s choice CT	PFS	R
ABRAZO	[131]	2	ADV	Talazoparib monotherapy	Single arm study	ORR	R
(NCT02034916)	[131]	2	ADV	Talazoparib monotherapy	Single arm study	ORR	R
(NCT02282345)	[75]	2	NADJ	Talazoparib monotherapy	Single arm study	Safety	R
Niraparib
BRAVO	[60]	3	ADV	Niraparib monotherapy	Physician’s choice CT	PFS	R
(NCT01905592)	[60]	3	ADV	Niraparib monotherapy	Physician’s choice CT	PFS	R
Rucaparib
(NCT00664781)	[132]	2	ADV	Rucaparib monotherapy	Single arm study	ORR, safety	NR
(NCT01074970)	[133]	2	ADJ	Rucaparib +	Cisplatin	2y-DFS	NR
(NCT01074970)	[133]	2	ADJ	Cisplatin	Cisplatin	2y-DFS	NR

ADJ Adjuvant, ADV Advanced, CBDCA Carboplatin, CT Chemotherapy, IDFS Interval disease-free survival, NADJ Neoadjuvant, NR Not yet recruiting, ORR Objective response rate, PFS Progression-free survival, PTX Paclitaxel, R Recruiting, 2y-DFS 2-year disease-free survival

ISSN: 1741-7015